Henrick J. Harwood and Tracy G. Myers, Editors, Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction, National Research Council

• Front MatterExecutive Summary1 Introduction and Background2 Clinical Trials3 Treatment, Financing, and Costs4 Behavioral Responses and ConsentReferencesAppendix A: Vaccines and Depot Medications for Drug Addiction: Rationale, Mechanisms of Action, and Treatment ImplicationsAppendix B: What Will We Learn from the FDA Clinical Trials Process and What Will We Still Want to Know About Immunotherapies and Depot Medications to Treat Drug Dependence?Appendix C: Putting Addiction Treatment Medications to Use: Lessons LearnedAppendix D: Adoption of Drug Abuse Treatment Technology in Speciality and Primary Care SettingsAppendix E: The Use of Immunotherapies and Sustained-Release Formulations in the Treatment of Drug Addiction: Will Current Law Support Coercion?Appendix F: Ethical Issues in Immunotherapies and Depot Mechanisms for Substance AbuseAppendix G: Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug AbuseAppendix H: Anticipating Unintended Consequences of Vaccine-Like Immunotherapies for Addictive Drug UseAppendix I: Vaccines and Immunotherapies to Control Addiction in Minors: The Legal FrameworkAppendix J: Biographical Sketches of Committee Members and Staff

Select Guide Rating